Observational studyAdvances in therapy2025

Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study.

Hideaki Kaneto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.